National and Kapodistrian University of Athens
Η ΣΥΣΤΗΜΑΤΙΚΗ ΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΤΩΝ ΟΓΚΩΝ ΤΗΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ
Abstract
dc:descriptionTHE AIM OF THIS STUDY WAS TO DETERMINE THE EFFICACY AND TOXICITY OF THE M-VEP COMBINATION TO THE PATIENTS WITH TRANSITIONAL CELL UROTHELIAL CANCER (TCUC). WE STUDIED 35 PATIENTS WITH TCUC AGED BETWEEN 44-79 YEARS OLD. THE 33 WERE MALE AND TWO WOMEN. THE PATIENT'S STAGE WAS T2N0M0 FOR 8 PATIENTS, T3AN0M0 FOR 8 PATIENTS, T3BN0M0 FOR 9 PATIENTS, T1-4N+M0 FOR 6 PATIENTS, T1-4N0M+ FOR 4 PATIENTS. ALL PATIENTS WERE TREATED WITH M-VEP CONSISTING OF METHOTRAXATE 25 MG/M2 THE 1ST, 15TH AND 22ND DAY, VINVLASTINE 2,5 MG /M2 THE 1ST, 15TH, 22ND DAY, CARBOPLATINUM 250 MG/M2 THE 1ST DAY AND EPIRUBICIN 25 MG/M2 THE 1ST DAY. THE M-VEP COMBINATION WAS GIVEN EVERY 29 DAYS IN AN OUTPATIENT BASIS. OVERALL RESPONSE RATE WAS 60% WITH 9 PATIENTS ACHIEVING COMPLETE RESPONSE AND 12 PATIENTS PARTIAL RESPONSE. FIVE PATIENTS HAD STABLE DISEASE AND 9 PROGRESSIVE DISEASE. THE RESPONSE DURATION RANGED BETWEEN 6 AND 38+ MONTHS (MEDIAN 16). PATIENTS SURVIVAL RANGED BETWEEN 6 AND 38+ MONTHS (MEDIAN 18,1). TWENTY ONE PATIENTS DEVELOPED MYELOSUPPRESSION, TWO PATIENTS INFECTION, 18 PATIENTS NAUSEA AND VOMITING,6 PATIENTS NEUROTOXICITY, ONE PATIENT ALLERGY AND TWO PATIENTS HAIR LOSS. THESE RESULTS SUGGEST THAT M-VEP REGIMEN IS A VERY EFFECTIVE TREATMENT FOR PATIENTS WITH TCUC AND CAN BE GIVEN IN AN OUTPATIENT BASIS.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 1992
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Πικραμένος, Διονύσιος
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/5279